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ABSTRACT
Chronic graft-versus-host disease (cGVHD), a common complication after stem cell transplant (SCT), has an
impact on morbidity and survival. Previous classification of cGVHD has not been reproducible or prognostic
for nonrelapse mortality (NRM). Recently the National Institutes of Health (NIH) consensus criteria were
proposed, but the ability of this classification to predict outcome of various subtypes of cGVHD is unknown.
Patients (N  110) undergoing an SCT for a hematologic malignancy and surviving until day 100 posttrans-
plant from 2001 to 2003 were studied. The overall survival (OS) using a landmark analysis at day 100 was 44%
versus 66% (no GVHD vs. GVHD, P  .026). The OS of patients with various types of GVHD as proposed by
the NIH criteria were significantly different (P < .0001). In a univariate analyses, this was more apparent when
patients with any acute features of GVHD were compared to classic cGVHD (3-year OS 46% vs. 68%, P 
.033). The 3-year NRM for the entire cohort was 21%, and was not affected by presence or absence of GVHD
or subtypes of GVHD. In a multivariable analysis, extensive cGVHD (hazard ratio [HR] 0.35, P  .015) and
having any acute feature of GVHD after day 100 (HR 3.36, P  .0144) were significant independent predictors
of survival. The OS with different NIH subtypes of GVHD after day 100 from SCT varies, and is superior for
patients with classic cGVHD.
© 2007 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Graft-versus-host disease (GVHD) is a common
omplication occurring after allogeneic stem cell
ransplant (SCT) [1,2]. Traditionally, this has been
lassiﬁed as acute (onset within ﬁrst 100 days of allo-
eneic SCT) and chronic (onset after 100 days of
llogeneic SCT). Acute GVHD (aGVHD) presents as
ermatitis, enteritis, and/or hepatitis, and is treated
ith short courses of high-dose steroids followed by a
ariable taper over several weeks [1]. Chronic GVHD
cGVHD) has protean manifestations that resemble a cariety of autoimmune disorders. The most common
lassiﬁcation still in use stratiﬁes cGVHD as limited
nd extensive based on clinical and laboratory features
3,4]. The prognostic signiﬁcance of this classiﬁcation
s unclear. Recently, the Seattle group published a
evised classiﬁcation, which stratiﬁes GVHD into
linical limited and extensive, and is based on mor-
hologic manifestations and extent of cGVHD. This
lassiﬁcation allows for decision making regarding
ystemic immunosuppression for patients with clinical
xtensive GVHD [4]. Both these classiﬁcations for
GVHD still use the 100-day time point, after which
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M. Jagasia et al.1208ny GVHD is called cGVHD. The National Insti-
utes of Health (NIH) published consensus criteria for
iagnosis of cGVHD. Manifestations of GVHD are
lassiﬁed according to various organ systems and sites
nvolved into distinctive, diagnostic, associated with,
r common to both aGVHD and cGVHD. GVHD
fter day 100 can now be classiﬁed as acute (persistent,
ecurrent, or late acute), classic cGVHD (features of
GVHD only), or overlap GVHD (features of acute
nd classic chronic). Each target organ affected is
cored for severity of involvement taking into account
ot only clinical or laboratory criteria, but also func-
ionality. Using this composite score, a new global
ssessment of cGVHD severity has been proposed [5].
he goal of this classiﬁcation is to establish a common
latform for subclassifying GVHD. The impact of
hese revised criteria on the incidence and outcome of
GVHD remains unknown. It is important to validate
hese criteria, to try and identify a subset of patients
ho may be at a higher risk of mortality, so future
linical studies can target this patient population.
In this study, we have retrospectively reclassiﬁed
VHD present after day 100 using the NIH consen-
us criteria, and show the impact of the revised clas-
iﬁcation on the incidence and outcome of cGVHD.
ur aim was to see if the presence of various subtypes
f GVHD after day 100 as proposed by the NIH
onsensus criteria affects survival or nonrelapse mor-
ality (NRM). The NIH consensus criteria have es-
ablished a severity scale for patients with cGVHD.
e have assessed the impact of severity in predicting
urvival or NRM among patients with cGVHD.
ATIENTS AND METHODS
All patients undergoing an allogeneic SCT for a
ematologic malignancy and surviving until day 100
fter transplant between January 1, 2001, and Decem-
er 31, 2003, at Vanderbilt University Medical Center
adults and pediatrics) and the associated Veterans
dministration Hospital were included in the initial
ohort (196 patients). All patients underwent trans-
lant on standard of care or institutional review board
IRB) approved protocols. All patients signed IRB-
pproved data consents. To study a homogenous co-
ort, patients with the following criteria were ex-
luded: received 2 allogeneic SCT, received donor
ymphocyte infusion, received chemotherapy for a re-
apse subsequent to allogeneic SCT, and received ad-
itional stem cells with or without prior standard dose
hemotherapy. The ﬁnal study cohort was comprised
f 110 patients. Detailed information regarding age,
ex (donor and recipient), diagnosis, preparative regi-
en, GVHD prophylaxis, disease status at transplant,
ytomegalovirus (CMV) serology, survival status, and
auses of death were reviewed for this cohort. aransplant Regimens
Patients received either myeloablative regimens
cyclophosphamide 120 mg/kg and total body irradi-
tion [TBI] 1200 cGy; cyclophosphamide 120 mg/kg
nd busulfan 16 mg/kg; cyclophosphamide 7200
g/m2, etoposide 2000 mg/m2, BCNU 400 mg/m2),
educed intensity (RIC) (ﬂudarabine 90 mg/m2 and
usulfan 8 mg/kg with TBI 400 cGy; ﬂudarabine 90
g/m2 and melphalan 140 mg/m2 with antithymocyte
lobulin [ATG]) or nonmyeloablative (ﬂudarabine 90
g/m2 and TBI 200 cGy) preparative regimens. Stem
ell sources were variable, and included peripheral
lood stem cells (PBSC), marrow, or cord blood from
elated or unrelated donors. Standard GVHD pro-
hylaxis regimens with either cyclosporine (CSP) and
ethotrexate (MTX) or cyclosporine (CSP) and my-
ophenolate mofetil (MMF) were used. All patients
eceived antimicrobial prophylaxis per institutional
uidelines. All patients received prophylaxis for Pneu-
ocystis carinii pneumonia after engraftment. Patients
ere monitored for CMV reactivation either with
ntigen assays or with polymerase chain reaction
PCR) assays, and were treated in a preemptive man-
er with ganciclovir or foscarnet.
GVHD
All patients were graded for aGVHD using the
lucksberg criteria [6] on a weekly basis until day 100,
nd the maximum grade during this time interval was
sed. Treatment of aGVHD was variable but the
ollowing general principles were used: grade II or
igher aGVHD was treated with 2 mg/kg of methyl-
rednisolone or an equivalent dose of prednisone for
-14 days followed by a taper of 10% every 5-7 days.
atients with isolated upper gut aGVHD could also
e treated with 1 mg/kg of methylprednisolone or an
quivalent dose of prednisone for 7-14 days followed
y a taper of 10% every 5-7 days. Treatment of steroid
efractory aGVHD was variable.
GVHD Diagnosis
Patients with persistent or new diagnosis of
VHD after day 100 were classiﬁed as cGVHD and
ere stratiﬁed as limited or extensive [3]. Treatment
f cGVHD was variable but followed some general
rinciples: patients with isolated mouth, ocular, or
inimal skin cGVHD were treated with topical im-
unosuppressant (eg, topical steroids). Patients with
igniﬁcant cGVHD were treated with calcineurin in-
ibitor along with systemic steroids (prednisone). Al-
hough duration and dosing of steroids were not stan-
ardized, patients typically received treatment until all
ymptoms of cGVHD were resolved or stabilized and
ubsequent tapers of immunosuppressive drugs were
ttempted.
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Chronic GVHD Grading Using NIH Criteria 1209eclassification of GVHD
A patient was deﬁned as having GVHD after day
00 if a patient had clinical symptoms, signs, or lab-
ratory manifestation of GVHD. Biopsies, when ob-
ained were reviewed. NIH consensus criteria for
iagnosis of cGVHD were applied stringently [5].
VHD after day 100 was reclassiﬁed as delayed acute,
ersistent acute, recurrent acute, classic chronic, over-
ap chronic. For persistent aGVHD, the assessment
as assigned at day 100. For delayed or recurrent
GVHD, the assessment was assigned at onset of
anifestation of GVHD. A patient was diagnosed as
aving cGVHD if there was presence of at least 1
iagnostic clinical sign of cGVHD or presence of at
east 1 distinctive manifestation conﬁrmed by perti-
ent biopsy or other relevant tests and exclusion of
ther possible diagnoses. If patients had features of
GVHD along with cGVHD, they were classiﬁed as
verlap cGVHD. Worsening of GVHD was deﬁnes
s requiring additional immunosuppressive therapy,
eescalation of ongoing therapy, or a clinical deterio-
ation attributable to GVHD while on immunosup-
ressive therapy taper. Data was reviewed serially and
ime point of peak severity was obtained. At that time
oint, GVHD was reclassiﬁed using the NIH consen-
us criteria.
Patients who had classic chronic or overlap chronic
ere scored using the NIH recommended criteria, and
global severity score of mild, moderate, or severe
as assigned [5]. Patients with delayed acute, persis-
ent acute, or recurrent acute were not scored, and
everity assessments were not assigned. Patients with
orsening of GVHD (as deﬁned above) were again
eclassiﬁed at the time of their peak severity. Severity
cores were assigned if they fulﬁlled criteria for classic
GVHD or overlap cGVHD.
tatistical Analysis
Descriptive statistics, including median and ranges
or continuous variables (Table 1) as well as percent-
ges and frequencies for categoric variables were cal-
ulated. Groups with nominal outcome were com-
ared using chi-square test; groups with continuous
utcomes were compared using Wilcoxon rank sum
est. We calculated overall survival (OS) from the day
f SCT to the day of death or last follow-up and
VHD-speciﬁc survival from the day of onset of
VHD to the day of death or last follow-up. Data
ere censored for patients alive at their last follow-up
isit. Kaplan-Meier survival curves were calculated for
ach cohort (or clinical group) and were compared
sing the log rank test.
The old classiﬁcation stratiﬁes cGVHD as limited
nd extensive. Recently, the NIH consensus criteria
ere published. The new criteria stratiﬁes GVHD
fter day 100 as acute (recurrent, late, or persistent), cverlap GVHD (features of both acute and classic)
nd chronic classic subtypes. Because of small sample
ize, in some analyses, patients with any acute feature
acute and overlap) were combined and compared
ith chronic classic. Cox proportional hazard regres-
ion analyses using penalized maximum likelihood es-
imation [7] was used to assess the relationship of old
nd new GVHD classiﬁcations to survival. To per-
orm the most robust analysis of the relationship be-
ween GVHD subtype and survival, GVHD subtype
as included as a time-dependent variable. The sub-
ype of GVHD was assessed at onset of GVHD (after
ay 100), and at maximum clinical worsening. The
tatus of GVHD subtype was permitted to vary over
ransplant to GVHD onset time, onset time to peak
ime, and peak time to last follow-up. The GVHD
ubtype was coded as “no GVHD” for the period of
CT to onset time. and coded separately according to
he GVHD status of onset and peak time. Statistical
ssumptions included that a patient with chronic ex-
ensive GVHD could not revert back to limited
GVHD. In the new classiﬁcation, assumptions in-
able 1. Baseline Charactersitics
N %
atients with GVHD after day 100 73 100
ge, median (years) 42 (range, 1-65)
ale/female 43/30 59/41
iagnoses*
Low risk 40 55
High risk 33 45
tem cell source
Marrow 23 32
Peripheral blood stem cells 47 64
Cord blood stem cells 3 4
reparative regimens
Myeloablative 56 77
Reduced intensity 6 5
Nonmyeloablative 13 18
LA match
HLA identical sibling 60 69
HLA matched unrelated 16 21
Other HLA match 7 10
VHD prophylaxis
CSP/MMF 18 25
CSP/MTX 51 70
CSP 4 5
ow risk: CML-CP 1 (n  6), acute leukemia in CR 1 (n  20),
multiple myeloma (n  6), low grade NHL (n  2), MDS
(n  5), CLL (n  1).
igh risk: CML beyond CP1 (n  1), acute leukemia beyond CR1
(n  23), NHL other than low grade/Hodgkin disease (n  8),
other  1.
LA indicates human leukocyte antigen; CSP, cyclosporine; MTX,
methotrexate; MMF, mycophenolate mofetil; GVHD, graft-
versus-host disease; NHL, non-Hodgkin lymphoma; CR, com-
plete remission; CLL, chronic lymphocytic leukemia; CP,
chronic phase; MDS, myelodysplastic syndromes; CML,
chronic myelogenous leukemia.luded that patients with chronic classic could not
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M. Jagasia et al.1210evert to only aGVHD. Other covariates included in
he Cox model were age at transplant and donor status
related versus unrelated). Cumulative incidence ofsRM was estimated using the Kaplan-Meier method
ith adjusting for relapse as a competing risk event
8,9]. Analyses were performed using SPSS version 13,
AS system version 9.1 and R version 2.1.1.
ESULTS
The ﬁnal study cohort consisted of 110 patients.
ne patient had bronchiolitis obliterans with organiz-
ng pneumonia (BOOP) after day 100 without any
VHD, and was unclassiﬁable. Vanderbilt adult ser-
ice, associated Veterans Hospital, and the pediatric
ervice contributed 72 (66%), 18 (17%), and 19 (17%)
atients, respectively. The median follow-up of the
urviving patients was 3.26 years (range: 2.02 to 5.1).
he 3-year OS was 50% (95% conﬁdence interval
CI] 0.38 to 0.62). A total of 73 (67%) patients were
dentiﬁed as having GVHD after day 100. Table 1
ives the detailed demographic information, and dis-
ase and transplant characteristics of the 73 patients
hat had GVHD at or after day 100.
o-GVHD Cohort Survival
Thirty-seven (33%) patients did not have any
VHD after day 100. The mean follow-up of patients
ithout GVHD was signiﬁcantly shorter than patients
ith GVHD after day 100 (1.8 years versus 2.5 years,
 .01). The OS of this group was signiﬁcantly
nferior compared to patients who developed GVHD
fter day 100 (44% versus 60%, P .026) (Figure 1A).
n this analysis, time was measured from day 100 until
ast follow-up. Twenty of 36 patients (55%) without
VHD died after SCT, 12 (60%) from relapse or
rogression of their disease, and 8 (40%) from trans-
lant related complications (TRM). Although the
auses of death were not signiﬁcantly different com-
ared with patients with GVHD after day 100, pa-
ients without GVHD had a signiﬁcantly shorter time
o death compared to patients with GVHD after day
00 (0.73 years versus 1.27 years, P  .002).
VHD Reclassification
Of the 73 patients with GVHD after day 100, 14
19%) were classiﬁed as limited cGVHD, and 59
81%) were classiﬁed as extensive cGVHD. One pa-
igure 1. A, OS for the entire cohort: stratiﬁed by presence or
bsence of GVHD after day 100 from SCT. Patients with GVHD
fter day 100 had a superior survival compared with patients without
VHD (44% versus 60%, P  .026). Time is measured from day
00 until last follow-up. B, OS: stratiﬁed by GVHD subtype as
roposed by NIH consensus criteria. Kaplan-Meier plot shows
igniﬁcant difference in survival of various GVHD subtypes (P 
0005). C, OS: classic cGVHD compared to other subtypes (persis-
ent, recurrent, delayed aGVHD, and overlap GVHD). Kaplan-
eier shows superior survival of classic cGVHD compared to otherubtypes (3-year OS 68% versus 46%, P  .033).
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Chronic GVHD Grading Using NIH Criteria 1211ient had BOOP without any systemic features of
VHD, and was not classiﬁable. The 3-year OS of
he limited cGVHD cohort was signiﬁcantly inferior
ompared to extensive cGVHD (21% versus 63.6%,
 .037).
The recently published NIH consensus criteria
ere used for the 73 patients who were classiﬁed as
aving GVHD after day 100. Based on this classiﬁca-
ion, GVHD after day 100 was reclassiﬁed as persis-
ent aGVHD (3 patients, 4%), recurrent aGVHD (22
atients, 30%), delayed aGVHD (2 patients, 3%),
verlap GVHD (features of both acute and classic
GVHD) (15 patients, 20%), and classic cGVHD (31
atients, 42%). One patient with BOOP was not clas-
iﬁable as any subset of aGVDH or cGVHD. Patients
ith limited cGVHD (14 patients) were reclassiﬁed as
ersistent acute (1 patient, 7%), recurrent acute (4
atients, 29%), and classic cGVHD (9 patients, 64%)
Table 2). Patients with extensive cGVHD (59 pa-
ients) were reclassiﬁed as persistent acute (2 patients,
%), delayed acute (2 patients, 3%), recurrent acute
18 patients, 31%), classic chronic (22 patients, 37%),
nd overlap GVHD (15 patients, 26%) respectively
Table 2).
Thirty-one (42%) had no worsening and 42 (58%)
ad worsening of their GVHD, respectively. Among
atients with classic cGVHD, 22 of 31 (65%) had
orsening of GVHD. This was signiﬁcantly higher
able 3. Distribution of Severity of Overlap and Classic cGVHD at On
Severity Score at GVHD Onset
Overlap GVHD (N  15) Number (%) Overla
ild 5 (33) Mild
oderate 9 (60) Modera
evere 1 (7) Severe
Classic cGVHD (N  31) Classic
ild 4 (13) Mild
oderate 18 (58) Modera
evere 9 (29) Severe
VHD indicates graft-versus-host disease; cGVHD, chronic graft-
Patients with no clinical worsening were assigned severity scores a
able 2. GVHD Reclassiﬁcation
New Classification
Old Classification Number (%)
Limited cGVHD
N  14
Extensive cGVHD
N  59
ersistent aGVHD 1 (7) 2 (3)
ecurrent aGVHD 4 (29) 18 (31)
elayed aGVHD — 2 (3)
verlap GVHD — 15 (26)
lassic cGVHD 9 (64) 22 (37)
GVHD indicates acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease.Clinical worsening was deﬁned as increased symptoms or signs (includinhan other GVHD types where 20 of 42 patients
47%) had worsening of GVHD (P  .046).
GVHD Severity
Of the 15 patients with overlap cGVHD, 5 pa-
ients (33%), 9 patients (60%), and 1 patient (7%)
ere classiﬁed as mild, moderate, or severe GVHD.
our (13%), 18 (58%), and 9 (29%) patients with
lassic cGVHD were classiﬁed as mild, moderate, and
evere, respectively (Table 3). Using the old classiﬁ-
ation, clinical worsening was seen in 7 of 14 (50%)
atients with limited cGVHD, and 35 of 59 (41%)
atients with extensive cGVHD. Nine of 15 patients
60%) with overlap GVHD had worsening compared
ith 22 of 31 (71%) patients with classic cGVHD
P  .457).
VHD Cohort Survival
OS. Of the 73 patients with GVHD after day 100,
7 patients died from transplant complications and 12
rom relapse or progression of the underlying disease
or an overall mortality of 40% (Table 4). There was
o difference in cause of death (relapse versus NRM
auses) in patients with limited compared with
GVHD (P  .568). The causes of death were not
ifferent when patients with classic cGVHD were
ompared with other subtypes of GVHD (P  .487).
edian time to development of GVHD were 89 days,
26 days, 119 days, 159 days, and 244 days for persis-
ent acute, delayed acute, recurrent acute, chronic
verlap, and classic cGVHD. The OS for patients
ith persistent acute, recurrent aGVHD, delayed
GVHD, overlap cGVHD, and classic cGVHD were
igniﬁcantly different (P  .0005) (Figure 1B). Three-
ear OS for patients with persistent acute, recurrent
GVHD, delayed aGVHD, overlap cGVHD, and
lassic cGVHD were 100%, 45%, 0%, 57%, and
7%, respectively (Figure 1B). This difference in sur-
ival (measured from day of SCT) was more apparent
hen patients with any aGVHD features (recurrent
Peak
ity Score at GVHD Peak* Patients with
Clinical Worsening†D (N  15) Number (%)
1 (7) 9 (60)
9 (60)
5 (33)
D (N  31)
2 (7) 22 (71)
16 (52)
13 (41)
host disease.
.set and
Sever
p GVH
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cGVH
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M. Jagasia et al.1212cute, delayed acute, and overlap chronic) was com-
ared with classic cGVHD (3-year OS 47.2% versus
6.7%, P  .015). This effect persisted when survival
as measured from onset of GVHD and patients with
lassic cGVHD (68% versus 46%) had a better
VHD-speciﬁc survival (calculated from onset of
VHD after day 100 to last follow-up) compared to
ther subtypes (P  .0336) (Figure 1C).
OSs of patients with mild (9 patients), moderate
27 patients), and severe (10 patients) GVHD at the
nset of GVHD diagnosis were not signiﬁcantly dif-
erent (P  .94) with 3-year OSs of 38.9% versus
3.8% versus 59.3% (Figure 2A). Similarly, the 3-year
S did not differ with respect to the peak severity of
he GVHD score. In these patients the 3-year survival
as 66.7%, 73.8%, and 59.3% for patients with mild
3 patients), moderate (25 patients), and severe (21
atients) GVHD (P  .41) (Figure 2B). Severities
ere not predictive of survival in patients with either
lassic cGVHD or overlap cGVHD.
onrelapse Mortality (NRM)
The 3-year cumulative NRM with relapse as a
ompeting risk for the entire cohort was 21%. There
as no difference in cumulative NRM in patients with
VHD after day 100 compared to patients who had
o GVHD after day 100. NRM in patients with
hronic classic GVHD was not different compared to
atients with other subtypes of GVHD (P  .57).
imited or extensive GVHD at onset had no impact
n cumulative NRM. Among patients with overlap
nd chronic classic GVHD, severity at onset or at peak
id not inﬂuence NRM.
ther Risk Factors
Other known risk factors that predict for survival
able 4. Cause of Death among Various GVHD Types
Cause of Death
GVHD Type N NRM RRM
Old Classification
imited* 14 4 (29%) 5 (36%)
xtensive* 59 8 (14%) 12 (20%)
NIH Classification
ersistent aGVHD 3 None None
elayed aGVHD 2 1 (50%) 1 (50%)
ecurrent aGVHD 22 6 (27%) 3 (2%)
verlap GVHD 15 4 (27%) 2 (13%)
hronic classic GVHD† 31 6 (19%) 2 (6%)
RM indicates nonrelapse mortality; GVHD, graft-versus-host
disease; RRM, death from relapse or progression; aGVHD,
acute graft-versus-host disease.
P  .568 comparing cause of death (limited versus extensive),
chi-square test.
P  .487 comparing cause of death (classic chronic versus other
subtypes), chi-square test.n patients with cGVHD were analyzed. There was no difference in survival, either OS or nonrelapse in pa-
ients with a platelet count of less than or more than
00  109/L at the time of diagnosis of GVHD.
imilarly, a bilirubin of less than or more than 3
g/dL at the time of diagnosis of GVHD had no
mpact on survival. Source of stem cell had no impact
n OS. Patients undergoing matched related donor
tem cell transplant had a better survival compared
ith patients undergoing alternate donor transplants
P  .029, 2-year OS: 73.9% versus 47.8%). Age
bove or below 40 years or as a continuous variable
ad no impact on survival.
ultivariate Analysis
Cox proportional multivariate models were con-
tructed using the old and the revised classiﬁcation.
igure 2. A, OS: stratiﬁed by severity at onset of GVHD (classic
nd overlap only) after day 100. Kaplan-Meier shows no difference
n survival (P  .94). B, OS: stratiﬁed by peak severity of GVHD
classic and overlap only) after day 100. Kaplan-Meier shows no
ifference in survival (P  .94).
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Chronic GVHD Grading Using NIH Criteria 1213ge at transplant and type of donor were adjusted for
n all models (Table 5). GVHD was analyzed as a
ime-dependent variable. When adjusted for donor
tatus and age, extensive GVHD was associated with
mproved survival with a hazard ratio (HR) of 0.35
95% CI 0.16 to 0.80, P  .015). Adjusted for donor
tatus and age at transplant, survival associated with
ny acute feature of GVHD after day 100 (includes
ate acute, delayed acute, recurrent acute, overlap) was
ot statistically different compared with classic
GVHD (HR 1.72, 95% CI 0.71 to 4.40, P  .2283).
Clinically, patients can transition from one subtype
f GVHD to another. To address these issues multivar-
ate models were constructed using rules. Patients were
llowed to transition from one subtype to another, ex-
ept patients with extensive cGVHD could not transi-
ion back to limited cGVHD, and classic or overlap
VHD could not transition to acute-only GVHD.
verlap GVHD and acute-only GVHD were com-
ined as 1 group because of sample size limitations.
djusted for donor status and age at transplant, exten-
ive cGVHD (accounting for subtype changes) was
ssociated with an HR of 0.36 (95% CI 0.16 to 0.91,
 .033). Any acute feature of GVHD (accounting
or subtype changes) after day 100 (includes late acute,
able 5. Multivariable Analyses
Variable Hazard Ratio (95% CI) P-value
Old Classification
imited cGVHD 1
xtensive cGVHD 0.35 (0.16, 0.80) .015
nrelated donor 1
elated donor 0.42 (0.19, 0.99) .049
ge at transplant 1.03 (0.97, 1.02) .813
Old Classification (Accounting for Subtype Changes)
imited cGVHD 1
xtensive cGVHD 0.36 (0.16, 0.91) .033
nrelated donor 1
elated donor 0.46 (0.20, 1.07) .071
ge at transplant 1.002 (0.97, 1.02) .89
NIH Consensus Classification
lassic cGVHD 1
cute feature of GVHD* 1.72 (0.71, 4.40) .228
nrelated donor 1
elated donor 0.61 (0.26, 1.49) .279
ge at transplant 1.00 (0.98, 1.02) .781
IH Consensus Classification (Accounting for Subtype Changes)
lassic cGVHD 1
cute feature of GVHD* 3.36 (1.25, 11.09) .0144
nrelated donor 1
elated donor 0.66 (0.29, 1.54) .333
ge at transplant 1.007 (0.98, 1.03) .555
VHD indicates graft-versus-host disease; cGVHD, chronic
graft-versus-host-disease.
Includes any acute feature of GVHD after day 100 (late acute,
recurrent acute, persistent acute, overlap GVHD).ecurrent acute, persistent acute, overlap GVHD) was lssociated with an HR of 3.36 (95% CI 1.25 to 11.09,
 .0144) when compared to classic cGVHD.
ISCUSSION
In this study we show the importance and the
mpact of the recently published NIH consensus cri-
eria on classiﬁcation of cGVHD. Patients with classic
GVHD have the best survival compared to patients
ith other subtypes of GVHD after day 100. Al-
hough, severity of GVHD may be important in de-
ision making regarding systemic immunosuppres-
ion, we could not show that it had an impact on
urvival.
GVHD after day 100 from transplant has histor-
cally been classiﬁed as cGVHD. In the past several
ears, with advances in nonmyeloablative transplant
nd RIC regimens, the natural history of aGVHD has
hanged, with a higher proportion of patients being
iagnosed with late-onset (after day 100) aGVHD
10,11]. Also, manifestations of aGVHD and cGVHD
re known to exist simultaneously. This makes the
rbitrary deﬁnition of any GVHD after day 100 being
alled cGVHD invalid. The most common classiﬁca-
ion system in use stratiﬁes cGVHD into limited and
xtensive [3]. This classiﬁcation was based on a report
f 20 patients. The prognostic signiﬁcance of this
lassiﬁcation is not known. In our study, patients with
imited (14 patients) and extensive (59 patients)
GVHD had a 3-year OS of 21% and 63%, respec-
ively (P  .037). This classiﬁcation is not reproduc-
ble or prognostic for late TRM. The incidence of
GVHD is variable among studies, and is inﬂuenced
y a variety of nonmodiﬁable (age of patient, age of
onor, HLA match) or modiﬁable factors (GVHD
rophylaxis, source of stem cells, graft manipulation)
12-16]. Aside from these, interobserver variability,
ack of standardized diagnostic criteria, and the pro-
ean manifestations of cGVHD have impaired the
evelopment of a common platform for diagnosis and
lassiﬁcation of cGVHD. Recently, the NIH consen-
us development project on criteria for clinical trials in
GVHD published the diagnosis and staging working
roup report [5]. The incidence and outcome of the
arious subtypes of GVHD and the impact of the
ewly developed scale for global assessment of severity
f cGVHD is unknown. We studied a cohort of pa-
ients transplanted in a 2-year time interval at a single
enter. Although limited by its retrospective nature
nd recording bias, the patient cohort was homo-
enous as patients receiving second transplant, che-
otherapy after transplant, or donor lymphocyte in-
usion after transplant were excluded. Because the
atural history of aGVHD prior to day 100 is well
nown, our cohort included patients who survived at
east until day 100. Survival of the patients signiﬁ-
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M. Jagasia et al.1214antly differed depending on subtype of GVHD after
ay 100. Patients with classic cGVHD had the best
utcome with a 68% 3-year OS. Patients with other
ubtypes of GVHD had a poor survival, with the worst
utcome in patients with recurrent aGVHD and de-
ayed aGVHD. Thus, our study identiﬁes a high-risk
roup of patients among patients who present with
VHD after day 100 from SCT. Patients with exten-
ive cGVHD had signiﬁcantly less risk of death com-
ared to limited cGVHD (HR 0.284; 95% CI 0.12-
.67). The causes of death (relapse versus NRM) were
ot signiﬁcantly different between the 2 groups (P 
568, Table 4). This is contradictory compared to
reviously published reports [17]. Possible explana-
ions for this contradictory result could include small
umber of limited cGVHD (n  14) to study the
mpact of this form of GVHD on survival. Another
ossible explanation is that in the previously published
tudy [17] the rate of misclassiﬁcation of extensive
GVHD as limited cGVHD study was reported as
5% to 67% for sibling transplants and 43% (83% of
ll cases) for unrelated transplants. The authors did
ot reclassify these patients because database limita-
ions prevented the application of limited and exten-
ive criteria with certainty. In our study, all interval
ata was available for stringent application of limited
nd extensive cGVHD criteria, and thus misclassiﬁca-
ion was minimized. Although OS of patients with
lassic cGVHD was signiﬁcantly better than other
VHD subtypes, the speciﬁc reason for this survival
eneﬁt could not be determined because of small
ample size.
GVHD subtypes were assigned at onset and at
linical worsening. Clinically, it is common for the
VHD subtype to change over follow-up. Multivari-
ble analyses accounting for these changes in subtype,
ontinued to show that extensive cGVHD was asso-
iated with a superior survival (HR 0.36, P  .033)
hen adjusted for donor status and age at transplant.
imilarly, accounting for GVHD subtype variation
uring clinical course, any acute feature of GVHD
fter day 100 (includes late acute, recurrent acute,
ersistent acute, overlap GVHD) was associated with
n inferior survival (HR 3.36, P  .0144) compared
ith classic cGVHD.
The NIH consensus report has suggested applying
lobal assessment of severity of GVHD after a diag-
osis of cGVHD has been made [5]. We applied this
cale only to patients with classic cGVHD and overlap
GVHD, as most of the individual organ function
coring on which the scale is based is targeted toward
GVHD symptoms. In our cohort of patients, severity
t onset or at peak of cGVHD activity did not corre-
ate with outcome. The global severity score as pro-
osed by the NIH consensus criteria may be useful as
descriptive clinical indicator of morbidity and the
eed for immunosuppressive therapy, but within theimits of our study, we did not ﬁnd that this score has
rognostic value with respect to survival.
Patients with any features of aGVHD after day
00 had the poorest OS compared with classic
GVHD (3-year OS 47.2% versus 66.7%, P  .015).
his patient population needs to be preferentially
nrolled on clinic trials of GVHD, exploring novel
gents. Patients with classic cGVHD have a 3-year OS
f 67%, and could preferentially be enrolled in studies
argeting topical treatment and organ-speciﬁc ap-
roaches. These patients should continue to be fol-
owed for late secondary complications of stem cell
ransplant. The NIH consensus criterion represents a
rue advance in subclassifying GVHD after day 100,
nd provides a common platform for clinical trials.
ur study validated the importance of subclassifying
VHD after day 100 as proposed by the NIH con-
ensus criterion. It is important to validate the pro-
osed NIH criteria in a prospective fashion in a mul-
icenter setting.
CKNOWLEDGMENTS
We thank Dr. Paul Martin, MD (Fred Hutchin-
on Cancer Research Center), for his review of the
anuscript and suggestions.
EFERENCES
1. Sullivan K. Graft vs. host disease. In: Blume KG, Forman SJ,
Appelbaum F, eds. Thomas’ Hematopoietic Cell Transplantation.
Oxford, UK: Blackwell Publishing, 2006:635-664.
2. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day
cyclosporine and prednisone for treatment of high-risk chronic
graft-v-host disease. Blood. 1988;72:555-561.
3. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man. A long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
4. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2003;9:215-233.
5. Filipovich AH,Weisdorf D, Pavletic S, et al. National Institutes
of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease: I. Diagnosis and
staging working group report. Biol Blood Marrow Transplant.
2005;11:945-956.
6. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A-matched sibling donors. Transplantation. 1974;18:295-
304.
7. Heinze G, Schemper M. A solution to the problem of mono-
tone likelihood in Cox regression. Biometrics. 2001;57:114-119.
8. Gray RJ. A class of K-sample tests for comparing the cumula-
tive incidence of a competing risk. Ann Stat. 1988;16:1141-
1154.
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation
of failure probabilities in the presence of competing risks:
new representations of old estimators. Stat Med. 1999;18:
695-706.
11
1
1
1
1
1
1
Chronic GVHD Grading Using NIH Criteria 12150. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host
disease after nonmyeloablative versus conventional hematopoi-
etic stem cell transplantation. Blood. 2003;102:756-762.
1. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of
chronic graft-versus-host disease after transplantation of periph-
eral blood stem cells versus bone marrow in allogeneic recipients:
long-term follow-up of a randomized trial. Blood. 2002;100:415-419.
2. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in
chronic graft-versus-host disease in patients with aplastic ane-
mia treated by marrow transplantation from HLA-identical
siblings. Ann Intern Med. 1983;98:461-466.
3. Niederwieser D, Pepe M, Storb R, et al. Factors predicting
chronic graft-versus-host disease and survival after marrow
transplantation for aplastic anemia. Bone Marrow Transplant.
1989;4:151-156.4. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors
for chronic graft-versus-host disease after HLA-identical
sibling bone marrow transplantation. Blood. 1990;75:2459-
2464.
5. Ochs LA, Miller WJ, Filipovich AH, et al. Predictive factors for
chronic graft-versus-host disease after histocompatible sibling
donor bone marrow transplantation. Bone Marrow Transplant.
1994;13:455-460.
6. Carlens S, Ringden O, Remberger M, et al. Risk factors for
chronic graft-versus-host disease after bone marrow transplan-
tation: a retrospective single centre analysis. Bone Marrow
Transplant. 1998;22:755-761.
7. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-
versus-host disease: association with treatment-related mortal-
ity and relapse. Blood. 2002;100:406-414.
